Disc Medicine (NASDAQ:IRON) Earns Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON) in a research report sent to investors on Friday, Benzinga reports. They currently have a $57.00 price objective on the stock.

A number of other research analysts have also recently commented on IRON. Raymond James increased their target price on Disc Medicine from $40.00 to $43.00 and gave the company an outperform rating in a research note on Friday, May 10th. HC Wainwright reiterated a buy rating and set a $70.00 price objective on shares of Disc Medicine in a research report on Wednesday, July 10th. Cantor Fitzgerald restated an overweight rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, May 28th. Finally, BMO Capital Markets reiterated an outperform rating and set a $70.00 price target (up from $50.00) on shares of Disc Medicine in a research report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Disc Medicine currently has a consensus rating of Moderate Buy and a consensus target price of $62.57.

Disc Medicine Trading Up 4.5 %

Shares of IRON opened at $45.02 on Friday. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $77.60. The company has a market cap of $1.11 billion, a PE ratio of -13.32 and a beta of 0.57. The stock has a 50-day moving average price of $43.71 and a 200-day moving average price of $46.67.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.08. As a group, analysts predict that Disc Medicine will post -4.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IRON. Amalgamated Bank boosted its position in Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after buying an additional 247 shares during the period. Strs Ohio boosted its holdings in shares of Disc Medicine by 66.7% during the fourth quarter. Strs Ohio now owns 1,000 shares of the company’s stock worth $57,000 after purchasing an additional 400 shares during the period. AJOVista LLC bought a new stake in shares of Disc Medicine in the fourth quarter worth about $63,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Disc Medicine in the second quarter worth about $129,000. Finally, ProShare Advisors LLC purchased a new position in Disc Medicine during the 1st quarter valued at about $211,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.